Applications

1674 – Testing for mismatch repair deficiency (dMMR) in endometrial cancer to help determine eligibility for PBS-subsidised dostarlimab

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status -
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome -

Application details

Reason for application

New MBS item.

Service or technology in this application

Immunohistochemistry (IHC) testing for identification of mismatch repair deficiency for eligibility to access dostarlimab on the PBS in patients with recurrent or advanced endometrial cancer.

Type: Co-dependent technology

Medical condition this application addresses

Patients with recurrent or advanced endometrial cancer which are mismatch repair deficient, who have progressed following prior treatment.

Consultation survey and deadlines

  • PASC consultation: Closed
  • MSAC consultation: TBA – please subscribe to the MSAC bulletin to be notified when consultation opens for this application.

Meetings to consider this application

  • PASC meeting: 12 to 13 August 2021
  • ESC meeting: -
  • MSAC meeting: -